Fact-checked by Grok 2 weeks ago

Serotonergic

Serotonergic refers to biological processes, neurons, and pathways that involve serotonin (5-hydroxytryptamine, or 5-HT), a monoamine neurotransmitter synthesized from the essential amino acid L-tryptophan primarily in the raphe nuclei of the brainstem and enterochromaffin cells of the gastrointestinal tract.^[1] This system plays a fundamental role in modulating neural activity, influencing a wide array of physiological functions including mood regulation, sleep-wake cycles, appetite control, pain perception, and gastrointestinal motility, with approximately 95% of the body's serotonin produced peripherally outside the central nervous system (CNS).^[1]^[2] In the CNS, serotonergic neurons originate from clusters in the raphe nuclei and project extensively to regions such as the cortex, hippocampus, and limbic system, where serotonin acts as an inhibitory or excitatory modulator depending on receptor subtypes.^[1] Synthesis begins with the rate-limiting step of hydroxylation by tryptophan hydroxylase, followed by decarboxylation, and the neurotransmitter is stored in vesicles before release into synaptic clefts upon neuronal depolarization, with reuptake regulated by serotonin transporters.^[1] Serotonin binds to 14 distinct receptors across seven families, most of which are G-protein-coupled receptors (GPCRs) that trigger intracellular signaling cascades to mediate effects like neuronal inhibition via hyperpolarization or excitation through cyclic AMP modulation.^[1]^[2]^[3] Beyond neurotransmission, the serotonergic system exerts receptor-independent influences, such as covalent attachment to proteins via transglutaminase, which contributes to processes like platelet activation and vascular tone regulation.^[2] Peripherally, it is critical for cardiovascular functions including vasoconstriction and platelet aggregation, pulmonary control of breathing, and endocrine regulation of insulin release and energy homeostasis.^[1]^[2] Dysregulation of serotonergic signaling is implicated in disorders such as depression, anxiety, and irritable bowel syndrome, making it a primary target for pharmacological interventions like selective serotonin reuptake inhibitors (SSRIs).^[1]

Overview

Definition and Scope

Serotonergic refers to substances, cells, receptors, or pathways involved in the modulation of serotonin (5-hydroxytryptamine, 5-HT) neurotransmission, a key monoamine signaling process in the central and peripheral nervous systems.^[1] This term encompasses elements that influence serotonin's synthesis, release, reuptake, or receptor activation, thereby regulating diverse physiological functions such as mood, cognition, and gastrointestinal motility.^[2] Serotonin itself is an indoleamine neurotransmitter with the molecular formula C_{10}H_{12}N_{2}O, biochemically derived from the essential amino acid L-tryptophan through a two-step hydroxylation and decarboxylation process.^[4]^[5] The serotonergic scope broadly includes serotonergic neurons originating primarily from raphe nuclei in the brainstem, which project widely to modulate neural circuits; pharmacological modulators like agonists and antagonists that selectively target serotonin receptors to mimic or block its effects; reuptake inhibitors, such as selective serotonin reuptake inhibitors (SSRIs), which enhance synaptic serotonin levels by blocking the serotonin transporter (SERT); and the seven main receptor families (5-HT_{1} through 5-HT_{7}), each with multiple subtypes exhibiting distinct signaling properties and tissue distributions.^[6]^[7]^[8] In distinction from dopaminergic or noradrenergic systems, which rely on catecholamine neurotransmitters (dopamine and norepinephrine) synthesized from tyrosine and featuring a catechol ring structure, the serotonergic system is defined by its unique indole-based pathways and non-catecholamine chemistry, leading to specialized roles in processes like emotional regulation rather than primary motor control or arousal.^[9]^[10] This separation underscores serotonin's independent contributions to neurotransmission while allowing for interactions with other monoaminergic systems.^[11]

Historical Discovery

The discovery of serotonin, or 5-hydroxytryptamine (5-HT), began in the late 1940s with investigations into blood serum components. In 1948, Maurice M. Rapport, Arda A. Green, and Irvine H. Page at the Cleveland Clinic isolated a vasoconstrictive substance from bovine serum during studies on blood clotting mechanisms, initially characterizing it as a potent agent that caused arterial constriction. This compound was formally named "serotonin" by Rapport, derived from "serum" and "tonic" to reflect its origin and vascular effects. Their work established serotonin's role in hemostasis and vasoconstriction, marking the first biochemical identification of the molecule in mammals.^[12] Parallel research in the early 1950s revealed serotonin's presence in the gastrointestinal tract. Italian pharmacologist Vittorio Erspamer had earlier isolated a bioactive amine from enterochromaffin cells in the gut mucosa, naming it "enteramine" in the 1930s and 1940s for its role in smooth muscle contraction. In 1952, Erspamer and colleagues definitively identified enteramine as 5-hydroxytryptamine, confirming its chemical identity with the serum factor through purification and bioassay techniques, thus unifying peripheral sources of the compound. This discovery highlighted serotonin's abundance in the gut, where it constitutes 95% of the body's serotonin, and expanded its recognized physiological scope beyond vascular functions.^[13]^[1] The extension of serotonin's role to the central nervous system occurred in the early 1950s, propelled by British pharmacologist John H. Gaddum and American researchers. In 1953, Betty M. Twarog and Irvine H. Page demonstrated serotonin's presence in mammalian brain tissue using fluorescence assays on extracts from dogs, rabbits, and mice, challenging the prior view that it was confined to peripheral organs and establishing its potential as a neural modulator. Gaddum's 1954 experiments further positioned serotonin as a neurotransmitter, showing that lysergic acid diethylamide (LSD) antagonized its effects on guinea pig ileum and suggesting a link to brain signaling. Throughout the 1950s and 1960s, studies solidified serotonin's involvement in vasoconstriction and emerging neural roles, with Twarog's findings paving the way for mapping brain serotonergic pathways.^[14]^[15] Advancements in the 1970s shifted focus to serotonergic neurons and receptor diversity through electrophysiological and binding techniques. George K. Aghajanian pioneered single-unit recordings in the mid-1970s, identifying slow-firing neurons in the dorsal raphe nucleus as serotonergic via responses to tryptophan loading and selective antagonists, providing direct evidence of their electrophysiological properties and autoinhibitory mechanisms.^[16] Concurrently, radioligand binding studies by Solomon J. Peroutka and Solomon H. Snyder in 1979 distinguished multiple serotonin receptor subtypes, with [³H]5-HT labeling high-affinity "5-HT₁" sites in brain membranes, separate from spiperone-sensitive sites later termed 5-HT₂, enabling precise classification and pharmacological targeting.^[17] These milestones transformed understanding of the serotonergic system from a peripheral hormone to a multifaceted neurotransmitter network.

Serotonergic System

Synthesis and Metabolism

Serotonin (5-hydroxytryptamine, 5-HT) is synthesized from the essential amino acid L-tryptophan in a two-step enzymatic process. The rate-limiting step involves the hydroxylation of L-tryptophan to 5-hydroxytryptophan (5-HTP) by tryptophan hydroxylase (TPH), followed by decarboxylation of 5-HTP to 5-HT by aromatic L-amino acid decarboxylase (AADC).^[18]^[19] This pathway occurs primarily in serotonergic neurons in the central nervous system and in peripheral tissues such as enterochromaffin cells in the gut.^[18] Two isoforms of TPH catalyze the initial hydroxylation: TPH1, which predominates in peripheral tissues including the gut and pineal gland, and TPH2, which is specific to the central nervous system and brainstem raphe nuclei.^[18]^[19] AADC, also known as 5-HTP decarboxylase, is a pyridoxal phosphate-dependent enzyme that rapidly converts 5-HTP to 5-HT.^[18] TPH activity requires the cofactor tetrahydrobiopterin (BH4), which facilitates the hydroxylation reaction.^[19] Following synthesis, 5-HT is stored in synaptic vesicles within serotonergic neurons via the vesicular monoamine transporter 2 (VMAT2), which uses a proton electrochemical gradient to sequester 5-HT from the cytoplasm, protecting it from degradation and enabling regulated release.^[20] Once released into the synaptic cleft, 5-HT is primarily degraded by monoamine oxidase A (MAO-A), an enzyme located on the outer mitochondrial membrane that catalyzes oxidative deamination to form 5-hydroxyindoleacetaldehyde, which is then oxidized by aldehyde dehydrogenase to the major metabolite 5-hydroxyindoleacetic acid (5-HIAA).^[19]^[21] 5-HIAA is water-soluble and excreted primarily in urine, serving as a biomarker for serotonin turnover.^[22] The synthesis and metabolism of 5-HT are tightly regulated to maintain homeostasis. TPH is subject to end-product feedback inhibition by 5-HT, which binds to an allosteric site on the enzyme to reduce its activity and prevent overproduction.^[19] Availability of L-tryptophan and BH4 also modulates TPH function, with BH4 levels influenced by stressors and inflammation that can impair synthesis.^[19] MAO-A expression and activity are similarly regulated, contributing to the balance between 5-HT levels and 5-HIAA production.^[21]

Distribution and Neurons

Serotonergic neurons in the central nervous system are predominantly clustered in the raphe nuclei of the brainstem, spanning the midbrain, pons, and medulla oblongata. The dorsal raphe nucleus (DRN) and median raphe nucleus (MRN) serve as the primary sources, originating nearly all serotonergic projections that innervate diverse brain regions, including the cerebral cortex, hippocampus, basal ganglia, thalamus, and spinal cord. These projections form extensive axonal networks that modulate widespread neural activity, with the DRN contributing more densely to forebrain targets like the cortex and hippocampus, while the MRN projects prominently to the hippocampus and septum.^[23]^[24]^[25] In the periphery, the vast majority of serotonin—approximately 90% of the total bodily content—is synthesized and stored in enterochromaffin cells of the gastrointestinal mucosa, particularly in the small intestine. These cells release serotonin locally to regulate gut motility and secretion. Platelets account for about 8% of total serotonin, sequestering it from plasma via active uptake for release during clotting and vascular responses. The pineal gland harbors only trace amounts of serotonin, where it functions mainly as a precursor for melatonin production under circadian control.^[26]^[27]^[28] Serotonergic neurons are characterized by the expression of tryptophan hydroxylase 2 (TPH2), the isoform-specific enzyme catalyzing the initial step in serotonin biosynthesis, which distinguishes central neurons from peripheral sources using TPH1. Identification often relies on TPH2 immunoreactivity, revealing their morphology as fusiform or multipolar cells with long, varicose axons. These neurons display distinct electrophysiological profiles, including tonic firing at low frequencies (1–5 Hz) to sustain ambient serotonin levels and phasic bursts in response to environmental cues, enabling flexible signaling.^[29]^[30]^[31] The serotonin transporter (SERT), encoded by the SLC6A4 gene, is highly expressed on presynaptic terminals and axons of serotonergic neurons, mediating sodium-dependent reuptake of serotonin to terminate synaptic transmission and recycle the neurotransmitter. This transporter ensures precise control of extracellular serotonin concentrations, with dense localization in raphe nuclei and projection fields. Species differences influence serotonergic anatomy; for example, rodents exhibit higher axonal densities in hippocampal regions compared to humans, reflecting variations in projection arborization.^[32]^[33]^[34]

Receptors and Signaling

Receptor Types

Serotonin receptors, also known as 5-HT receptors, are classified into seven main families (5-HT1 through 5-HT7) with a total of 14 subtypes, where most belong to the G-protein-coupled receptor (GPCR) superfamily, except for the 5-HT3 family, which consists of ligand-gated ion channels.^[35]^[36] The GPCR families (5-HT1, 5-HT2, 5-HT4–5-HT7) feature a characteristic seven-transmembrane domain architecture, enabling orthosteric binding of serotonin and agonists in a pocket formed by transmembrane helices III, V, VI, and VII.^[35]^[37] The 5-HT1 family includes five subtypes (5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, and 5-HT1F) that couple to Gi/o proteins, mediating inhibitory effects by decreasing cyclic AMP levels.^[35]^[38] These receptors often function as presynaptic autoreceptors, particularly 5-HT1A and 5-HT1B subtypes, which provide negative feedback to regulate serotonin release in the raphe nuclei.^[39]^[40] The orthosteric binding site in 5-HT1B and 5-HT1D accommodates selective agonists like sumatriptan, which targets these subtypes for therapeutic applications.^[35]^[41] The 5-HT2 family comprises three subtypes (5-HT2A, 5-HT2B, and 5-HT2C), all coupling to Gq proteins to stimulate phospholipase C and increase intracellular calcium.^[42] These receptors are predominantly postsynaptic and play key roles in excitatory signaling, with the 5-HT2A subtype being central to the effects of serotonergic psychedelics through its activation by agonists like psilocybin.^[43]^[44] In contrast, the 5-HT3 receptor is an ionotropic, nicotinic acetylcholine receptor-like ligand-gated cation channel that permits the influx of sodium and calcium ions and the efflux of potassium ions upon serotonin binding, leading to rapid neuronal depolarization.^[45] This family mediates nausea and emesis, particularly in response to chemotherapeutic agents, via activation in the brainstem and enteric nervous system.^[46]^[47] The remaining families include 5-HT4, 5-HT5, 5-HT6, and 5-HT7, with 5-HT4, 5-HT6, and 5-HT7 coupling to Gs proteins for stimulatory effects via increased adenylyl cyclase activity and cAMP elevation, while 5-HT5 subtypes (5-HT5A and 5-HT5B) couple to Gi/o for inhibition.^[48]^[35] The 5-HT4 receptor promotes gastrointestinal motility through its expression in enteric neurons and smooth muscle.^[49] The 5-HT7 receptor contributes to thermoregulation by modulating hypothalamic circuits involved in temperature control.^[50]

Intracellular Pathways

Serotonin receptors, predominantly G-protein-coupled receptors (GPCRs), trigger a variety of intracellular signaling cascades upon ligand binding, modulating second messenger systems to influence cellular responses. The 5-HT1 and 5-HT5 receptor families couple to Gi/o proteins, which inhibit adenylyl cyclase activity, resulting in decreased cyclic AMP (cAMP) levels and subsequent reduction in protein kinase A (PKA) activation.^[51] In contrast, 5-HT2 receptors associate with Gq/11 proteins, stimulating phospholipase C (PLC) to hydrolyze phosphatidylinositol 4,5-bisphosphate into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG); IP3 promotes calcium release from intracellular stores, while DAG activates protein kinase C (PKC).^[51] The 5-HT4, 5-HT6, and 5-HT7 receptors couple to Gs proteins, enhancing adenylyl cyclase to elevate cAMP and activate PKA, thereby facilitating phosphorylation of downstream targets involved in gene transcription and ion channel modulation.^[51] The 5-HT3 receptor stands apart as a pentameric ligand-gated ion channel rather than a GPCR, enabling rapid depolarization through direct influx of sodium and efflux of potassium ions upon serotonin binding, without reliance on G-protein intermediaries or second messengers.^[38] Beyond primary G-protein pathways, beta-arrestin recruitment plays a critical role in desensitization and internalization of several 5-HT receptors, including 5-HT2A and 5-HT4, by uncoupling receptors from G-proteins and promoting endocytosis, which limits signaling duration and may scaffold alternative effectors.^[52] Serotonergic signaling integrates with broader networks through crosstalk, notably activating the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway and the phosphoinositide 3-kinase (PI3K)/Akt pathway, often independently of canonical G-protein routes; these interactions drive gene expression changes, such as c-fos induction, influencing neuronal plasticity and survival.^[38] A key regulatory feedback loop involves presynaptic 5-HT1A autoreceptors, which, via Gi/o-mediated inhibition of adenylyl cyclase, suppress voltage-gated calcium channels and activate potassium channels, thereby reducing serotonin release and maintaining homeostasis in serotonergic neurons.^[53]

Physiological Functions

Central Nervous System Roles

Serotonin plays a pivotal role in modulating mood within the central nervous system, primarily through the 5-HT1A receptor, which is densely expressed in the hippocampus, prefrontal cortex, and raphe nuclei. Activation of postsynaptic 5-HT1A receptors in these regions reduces anxiety by hyperpolarizing neurons and inhibiting excitatory neurotransmission, thereby promoting emotional stability.^[54] Low levels of serotonin have been linked to depression via the monoamine hypothesis, which posits that deficiencies in serotonergic transmission contribute to depressive symptoms by impairing mood regulation circuits.^[55] Serotonin also modulates pain perception through descending inhibitory pathways from the brainstem to the spinal cord, where 5-HT1A and 5-HT3 receptors primarily exert antinociceptive effects by hyperpolarizing dorsal horn neurons and enhancing inhibitory neurotransmission, although certain 5-HT2 and 5-HT3 subtypes can facilitate pain under specific conditions. Dysregulation of these pathways contributes to chronic pain states.^[56] In sleep-wake regulation, serotonergic neurons originating from the raphe nuclei project widely to arousal-promoting areas such as the hypothalamus and cortex, facilitating wakefulness through 5-HT2 receptor activation, which enhances cortical excitability and vigilance. These projections also suppress rapid eye movement (REM) sleep by inhibiting cholinergic neurons in the brainstem, preventing the phasic bursts associated with dreaming states.^[57]^[58] Serotonin influences cognition via specific receptor subtypes in key brain regions; for instance, 5-HT4 receptors in the hippocampus enhance memory consolidation by promoting long-term potentiation and synaptic plasticity in learning circuits. In the prefrontal cortex, 5-HT2A receptors modulate decision-making by altering executive function and attentional control through interactions with glutamatergic pathways.^[59]^[60] Regarding appetite and reward, hypothalamic 5-HT2C receptors mediate satiety signaling by activating pro-opiomelanocortin neurons, which suppress feeding behavior and promote energy homeostasis. In the nucleus accumbens, serotonergic modulation fine-tunes reward processing by dampening excessive dopamine release, thereby balancing motivational drive and preventing overconsumption of rewarding stimuli.^[61]^[62] Serotonin contributes to sensory processing through 5-HT2A receptor activation in cortical layers, particularly in response to hallucinogens like psilocybin, which induce perceptual alterations by increasing pyramidal neuron excitability and disrupting sensory gating in visual and auditory cortices.^[63]

Peripheral and Enteric Roles

Serotonin plays a critical role in the enteric nervous system, where approximately 95% of the body's serotonin is produced and stored in enterochromaffin cells of the gastrointestinal tract.^[64] This serotonin modulates gut motility through various receptors; for instance, activation of 5-HT4 receptors on enteric neurons enhances acetylcholine release, thereby accelerating the peristaltic reflex and promoting propulsive motility.^[64] Additionally, 5-HT3 receptors on vagal afferent fibers contribute to the vomiting reflex, where serotonin release from enterochromaffin cells in response to stimuli like chemotherapy triggers emesis, a mechanism effectively blocked by 5-HT3 antagonists.^[64] In the cardiovascular system, serotonin facilitates platelet aggregation via 5-HT2A receptors, promoting thrombus formation and aiding in hemostasis during vascular injury.^[65] It also induces vasoconstriction through 5-HT1B and 5-HT1D receptors on vascular smooth muscle, particularly in cranial arteries, which helps regulate blood flow and contributes to the therapeutic effects of triptans in migraine treatment.^[66] Serotonin modulates immune responses by being released from mast cells at sites of inflammation, where it attracts additional immune cells and amplifies local reactions.^[67] Furthermore, 5-HT7 receptors on lymphocytes regulate cytokine production, such as promoting interleukin-1β and interleukin-8 release from dendritic cells while suppressing interleukin-12 and tumor necrosis factor, thereby influencing inflammatory processes.^[68] In endocrine functions, serotonin serves as a precursor for melatonin synthesis in the pineal gland, where it is acetylated to N-acetylserotonin and then methylated to form melatonin, regulating circadian rhythms.^[69] In the pancreas, serotonin produced by beta cells enhances glucose-stimulated insulin secretion via 5-HT3 receptors, which depolarize the cell membrane to facilitate exocytosis during nutrient intake.^[70] Regarding bone metabolism, serotonin acts through 5-HT2B receptors on osteoblasts to control their proliferation and recruitment, thereby influencing bone formation and mass; disruption of this pathway, as seen in receptor knockout models, leads to reduced bone density.^[71]

Clinical Relevance

Disorders Associated with Dysregulation

Dysregulation of the serotonergic system has been implicated in various mental health disorders, particularly those involving mood and obsessive behaviors. In major depressive disorder (MDD), the serotonin hypothesis, originally proposing deficits in brain serotonin activity as a cause of depressive symptoms, has been influential in research and treatment development, though recent comprehensive reviews indicate a lack of consistent evidence supporting reduced central serotonin neurotransmission as a primary cause.^[55]^[72] Similarly, low serotonin levels are associated with anxiety disorders, where alterations in serotonergic signaling, including reduced availability in key brain regions, exacerbate fear responses and emotional dysregulation.^[73] In obsessive-compulsive disorder (OCD), dysregulation of serotonin pathways, potentially involving imbalances in receptor function and transporter activity, underlies repetitive behaviors and intrusive thoughts, with neuroimaging studies revealing altered serotonergic activity in cortico-striatal circuits.^[74] Conversely, in schizophrenia, hyperactivity of 5-HT2A receptors in cortical regions is linked to positive symptoms such as hallucinations and delusions, contributing to disrupted sensory processing and cognition.^[75] Neurological conditions also reflect serotonergic imbalances, notably in migraine pathogenesis, where activation of 5-HT1B and 5-HT1D receptors in the trigeminovascular system modulates pain signaling; during attacks, fluctuating serotonin levels lead to vasodilation and neurogenic inflammation in cerebral vessels.^[76] In autism spectrum disorder (ASD), polymorphisms in the serotonin transporter (SERT) gene are associated with increased risk, as these variants alter serotonin reuptake and availability during neurodevelopment, potentially disrupting social and sensory processing circuits.^[77] Gastrointestinal disorders demonstrate peripheral serotonergic dysregulation, as in irritable bowel syndrome (IBS), where altered enteric serotonin signaling—often involving elevated 5-HT release or receptor hypersensitivity—affects gut motility and secretion, leading to diarrhea-predominant or constipation-predominant subtypes.^[78] Carcinoid syndrome, resulting from serotonin overproduction by neuroendocrine tumors, causes systemic effects like flushing and diarrhea due to excessive 5-HT secretion into the bloodstream, which stimulates smooth muscle and vascular responses.^[79] Cardiovascular pathologies include primary pulmonary hypertension, where overexpression of the serotonin transporter in pulmonary artery smooth muscle cells enhances intracellular serotonin accumulation, promoting cell proliferation and vascular remodeling.^[80] Genetic factors further underscore vulnerability; the short allele of the 5-HTTLPR polymorphism in the SERT gene was initially associated with heightened depression risk, particularly under stress, as it reduces transporter efficiency and serotonin reuptake, amplifying emotional reactivity, though subsequent meta-analyses have not consistently replicated this interaction.^[81]^[82]

Therapeutic Interventions

Therapeutic interventions targeting the serotonergic system primarily involve pharmacological agents that modulate serotonin levels or receptor activity to address various psychiatric and neurological conditions. These include reuptake inhibitors, receptor agonists, and antagonists, which have become cornerstones in treating disorders such as major depressive disorder (MDD), anxiety, migraine, nausea, and psychosis.^[83]^[84] Selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine and sertraline, exert their effects by blocking the serotonin transporter (SERT), thereby increasing synaptic serotonin concentrations and enhancing serotonergic transmission. These agents are first-line treatments for MDD and anxiety disorders due to their efficacy in alleviating symptoms like persistent sadness and excessive worry, with clinical trials demonstrating significant symptom reduction after 4-6 weeks of use.^[83]^[85] Fluoxetine, the first approved SSRI, and sertraline are particularly noted for their favorable safety profiles and lower risk of side effects compared to older antidepressants.^[83] Serotonin-norepinephrine reuptake inhibitors (SNRIs), exemplified by venlafaxine, inhibit both SERT and the norepinephrine transporter, leading to elevated levels of serotonin and norepinephrine in the synaptic cleft. This dual mechanism provides broader therapeutic benefits, particularly for MDD and generalized anxiety disorder, where venlafaxine has shown superior efficacy in reducing symptoms of depression and anxiety in patients unresponsive to SSRIs alone.^[84]^[86] Serotonergic agonists include triptans like sumatriptan, which act as selective 5-HT1B/1D receptor agonists to constrict cranial blood vessels and inhibit pain pathway activation, making them effective for acute migraine treatment. Sumatriptan relieves migraine headaches with or without aura, with clinical studies reporting pain relief in 60-70% of patients within 2 hours of administration.^[87]^[88] Another agonist, buspirone, functions as a partial 5-HT1A receptor agonist, modulating serotonergic activity to reduce anxiety without sedative effects, and is FDA-approved for generalized anxiety disorder, showing efficacy comparable to benzodiazepines but with less risk of dependence.^[89]^[90] Antagonists targeting specific serotonin receptors also play key roles; ondansetron, a 5-HT3 receptor antagonist, blocks serotonin-mediated activation in the chemoreceptor trigger zone and vagal afferents, effectively preventing nausea and vomiting associated with chemotherapy and postoperative states. Clinical evidence supports its use as a first-line antiemetic, with rapid onset and high tolerability.^[46] In psychosis treatment, atypical antipsychotics such as risperidone incorporate 5-HT2A receptor antagonism alongside dopamine D2 blockade, which helps alleviate positive symptoms like hallucinations while minimizing extrapyramidal side effects compared to typical antipsychotics. Risperidone's serotonergic modulation contributes to its efficacy in schizophrenia, with meta-analyses confirming symptom improvement in 50-70% of patients.^[91]^[92] Emerging applications of serotonergic psychedelics include psilocybin, a 5-HT2A receptor agonist, which has shown promise in depression therapy through clinical trials demonstrating rapid and sustained reductions in MDD symptoms following single-dose administration with psychological support. In phase II trials, psilocybin led to response rates of over 50% at 1-week follow-up, persisting for months in some participants. In June 2025, a phase 3 trial of COMP360 psilocybin for treatment-resistant depression met its primary endpoint, supporting further evaluation for potential approval.^[93]^[94]^[95] Similarly, MDMA-assisted therapy for post-traumatic stress disorder (PTSD) leverages MDMA's serotonergic effects, including serotonin release and reuptake inhibition, to facilitate emotional processing; phase III trials reported 67% of participants no longer meeting PTSD diagnostic criteria after three sessions. However, as of 2025, MDMA-assisted therapy has not received FDA approval for PTSD treatment, following a 2024 rejection, though research continues.^[96]^[97]^[98]

Research and Developments

Experimental Models

Genetic models have been instrumental in elucidating the role of serotonin in brain function by selectively disrupting key components of the serotonergic system. Tryptophan hydroxylase 2 (TPH2) knockout mice, which lack the brain-specific enzyme for serotonin synthesis, exhibit complete absence of serotonin in raphe neurons, leading to profound behavioral deficits such as growth retardation and altered autonomic control.^[99]^[100] These models demonstrate serotonin deficiency's impact on emotional regulation, with TPH2-deficient mice showing exaggerated aggression alongside reduced anxiety-like behaviors in standard assays.^[101] Similarly, serotonin transporter (SERT) knockout mice display a complex phenotype characterized by high baseline anxiety, depressive-like behaviors, and hypolocomotion, reflecting disrupted serotonin reuptake and extracellular accumulation.^[102]^[103] These genetic alterations provide causal insights into serotonin's modulatory effects on mood and stress responses without confounding pharmacological effects. Pharmacological approaches enable precise visualization and manipulation of serotonergic activity in vivo. Positron emission tomography (PET) imaging using the radioligand [11C]DASB allows quantification of SERT binding potential with high reproducibility, facilitating studies of serotonin transporter density in brain regions like the midbrain and thalamus.^[104] This technique has been validated for parametric imaging of binding parameters, offering reliable measures for investigating dysregulation in psychiatric conditions.^[105] Optogenetics provides temporal control over serotonergic neurons, particularly those in the dorsal raphe nucleus, where channelrhodopsin-mediated activation suppresses operant responding for rewards and modulates feeding behavior through projections to the ventral tegmental area and arcuate nucleus.^[106]^[107] Such targeted stimulation reveals serotonin's inhibitory role in reward processing and seizure-induced respiratory arrest, highlighting circuit-specific functions.^[108] In vitro techniques offer detailed examination of serotonergic receptor properties at the cellular level. Patch-clamp electrophysiology on 5-HT3 receptors, expressed in neuronal cultures or cell lines, reveals their ligand-gated ion channel characteristics, including rapid desensitization and conductance properties around 10-20 pS for single channels.^[109]^[110] These recordings demonstrate 5-HT3 channels' permeability to cations like sodium and calcium, underpinning their role in fast excitatory neurotransmission.^[111] Heterologous expression systems, such as human embryonic kidney (HEK) 293 cells transfected with serotonin receptors (e.g., 5-HT1A or 5-HT1B), enable functional assays of G-protein coupled signaling, including Gi/o-mediated inhibition of adenylyl cyclase and downstream ERK activation.^[112]^[113] This approach confirms receptor pharmacology and allosteric modulation, such as zinc's inhibitory effects on 5-HT7 receptors, providing a controlled platform for drug screening.^[114] Behavioral assays in rodents serve as standardized proxies for assessing serotonergic influences on emotion and motivation. The forced swim test, where immobility duration reflects despair-like behavior, is widely employed for screening antidepressants that enhance serotonergic transmission, with reductions in immobility indicating efficacy comparable to selective serotonin reuptake inhibitors.^[115]^[116] Serotonergic lesions or manipulations in this paradigm alter swim persistence, linking serotonin to adaptive coping under stress. The elevated plus maze evaluates anxiety through exploration of open versus closed arms, where serotonergic depletion via lesions increases open-arm entries, signifying reduced anxiety, while agonists at 5-HT1A receptors can induce anxiogenic effects.^[117]^[118] These assays validate serotonin's bidirectional role in anxiety modulation, with outcomes sensitive to genetic background and prior experience.^[119] Human proxy measures bridge preclinical findings to clinical relevance by indirectly assessing central serotonergic activity. Cerebrospinal fluid (CSF) measurement of 5-hydroxyindoleacetic acid (5-HIAA), the primary serotonin metabolite, correlates with brain serotonin turnover, with lower levels associated with suicidal behavior and mood disorders in patients.^[120]^[121] This biomarker provides a stable index of serotonergic function, often sampled via lumbar puncture for diagnostic insights. Functional magnetic resonance imaging (fMRI) combined with acute tryptophan depletion (ATD), which transiently lowers brain serotonin synthesis by dietary means, reveals altered neural responses in reward and emotion circuits, such as reduced connectivity in the raphe nuclei and anterior-posterior shifts in activation patterns during cognitive tasks.^[122]^[123] ATD-induced changes normalize aberrant reward processing in conditions like anorexia nervosa, underscoring serotonin's role in flexible decision-making.^[124]

Emerging Therapies

Psychedelic-assisted therapies targeting serotonergic pathways, particularly through 5-HT2A receptor agonism, have gained significant attention for treating major depressive disorder (MDD). In 2019, the FDA granted Breakthrough Therapy designation to psilocybin for MDD based on promising early trial data showing rapid and sustained antidepressant effects.^[125] Ongoing phase 2 and 3 trials in the 2020s, such as those evaluating a single 25 mg dose of psilocybin, have demonstrated substantial reductions in depression severity, with remission rates around 25% at 12 weeks post-treatment.^[126] A phase 2 trial of CYB003, a deuterated psilocybin analog, reported higher remission rates of up to 75% at 4 months post-treatment, leading to FDA Breakthrough Therapy designation in 2024.^[127] Additionally, ketamine and its analogs indirectly enhance 5-HT2A receptor function, contributing to their rapid antidepressant actions beyond primary NMDA antagonism, as evidenced by preclinical studies showing blockade of receptor desensitization and increased serotonergic signaling.^[128] Novel serotonergic modulators are advancing as multimodal agents for psychiatric conditions. Vilazodone, an approved antidepressant combining selective serotonin reuptake inhibition with partial agonism at 5-HT1A receptors, represents a prototypical example of this approach, promoting enhanced serotonin transmission and potentially faster onset of action compared to traditional SSRIs.^[129]^[130] For schizophrenia, 5-HT7 receptor antagonists show promise in addressing cognitive deficits, with preclinical models indicating improved prefrontal cortex function and reduced negative symptoms through modulation of glutamatergic and dopaminergic pathways.^[131]^[132] Clinical exploration, including imaging studies of 5-HT7 antagonism in related mood disorders, supports further investigation into their therapeutic potential.^[133] Interventions targeting the gut-brain axis via serotonergic mechanisms are emerging for comorbid conditions like irritable bowel syndrome (IBS) and depression. Fecal microbiota transplantation (FMT) has been shown in 2023 multi-omics studies to reshape gut microbiota, elevate enteric serotonin levels, and alleviate symptoms of constipation, anxiety, and depression in affected patients.^[134] A 2023 meta-analysis further confirmed FMT's efficacy in reducing IBS symptoms, with associated improvements in mood linked to microbiota-driven serotonin modulation.^[135] Recent meta-analyses up to 2025 reinforce FMT as an adjunctive therapy for depressive symptoms, particularly in IBS cohorts, by influencing peripheral serotonin production.^[136] Gene therapy approaches are in early preclinical stages for serotonergic dysregulation. TPH2 deficits have been observed in some animal models of depression, highlighting potential for strategies to boost brain serotonin synthesis.^[137]^[138] Recent clinical trials from 2024 to 2025 highlight serotonergic innovations for metabolic and neurological disorders. Selective 5-HT2C receptor agonists have been investigated for obesity, as exemplified by lorcaserin, which showed appetite suppression and weight reduction through hypothalamic serotonin signaling but was withdrawn from the market in 2020 due to potential cancer risks.^[139]^[140] For migraine, serotonin-modulating neuromodulation devices, such as remote electrical neuromodulation (REN) systems, have demonstrated efficacy in acute treatment, reducing headache days by activating endogenous serotonergic pathways akin to triptans without pharmacological risks.^[141]^[142]

References

[1]
Physiology, Serotonin - StatPearls - NCBI Bookshelf - NIH
Jul 30, 2023 · Serotonin, or 5-hydroxytryptamine (5-HT), is a neurotransmitter with an integral physiological role in the human body; it regulates various activities.
[2]
The Expanded Biology of Serotonin - PMC - NIH
Serotonin is perhaps best known as a neurotransmitter that modulates neural activity and a wide range of neuropsychological processes.
[3]
Serotonin | C10H12N2O | CID 5202 - PubChem - NIH
Serotonin ; Molecular Formula. C10H12N2O ; Synonyms. serotonin; 5-HYDROXYTRYPTAMINE; 50-67-9; 3-(2-Aminoethyl)-1H-indol-5-ol; Enteramine ; Molecular Weight. 176.21 ...
[4]
Tryptophan Metabolic Pathways and Brain Serotonergic Activity
Apr 8, 2019 · The essential amino acid L-tryptophan (Trp) is the precursor of the monoaminergic neurotransmitter serotonin (5-hydroxytryptamine, 5-HT).
[5]
Review: 5-HT1, 5-HT2, 5-HT3 and 5-HT7 Receptors and their Role ...
Serotonin [5-HydroxyTryptamine (5-HT)] is a neurotransmitter with seven families (5-HT1–5-HT7) and approximately 15 receptor subtypes.
[6]
Serotonin Syndrome: Pathophysiology, Clinical Features ...
Sep 9, 2019 · Serotonergic signalling is a tightly regulated process characterised by a combination of feedback loops, multiple reuptake mechanisms, and ...
[7]
Biochemistry, Serotonin - StatPearls - NCBI Bookshelf - NIH
Serotonin is a monoamine neurotransmitter that plays a role in several complex biological functions.[1][2] Its common abbreviation is 5-HT.
[8]
Serotonin - Basic Neurochemistry - NCBI Bookshelf - NIH
The serotonin transporter (SERT) is located on serotonergic neurons. Evidence for this comes from studies showing that the selective lesioning of serotonergic ...
[9]
Physiology, Neurotransmitters - StatPearls - NCBI Bookshelf - NIH
Serotonin, a neurotransmitter that controls several neuropsychiatric processes, has been implicated in the pathogenesis of depression. Research has shown ...
[10]
Serotonin versus catecholamine deficiency: behavioral and neural ...
Mar 17, 2015 · This study showed that serotonin and catecholamines have common and differential roles in the pathophysiology of depression.
[11]
Identification of Enteramine, the Specific Hormone of the ... - Nature
Enteramine is the specific secretion or storage product of the typical enterochromaffin cells of the gastrointestinal mucosa of Vertebrata and Ascidia.
[12]
Serotonin Content of Some Mammalian Tissues and Urine and a ...
Serotonin Content of Some Mammalian Tissues and Urine and a Method for Its Determination. Betty M. Twarog, and; Irvine H. Page. Betty M. Twarog.
[13]
The Discovery of Serotonin and its Role in Neuroscience - Nature
Aug 1, 1999 · Enteramine had a relatively extensive place in the scientific literature until 1952, when it was established as the same substance which Irvine ...
[14]
Tryptophan Hydroxylase-2-Mediated Serotonin Biosynthesis ... - PMC
Mar 2, 2023 · Tryptophan, in addition to being the sole precursor of serotonin, is a well-known and important precursor of kynurenine (Kyn), vitamin B3, as ...
[15]
Tryptophan Metabolism in Depression: A Narrative Review ... - MDPI
This narrative review aims to explore tryptophan metabolism (particularly in the serotonin and kynurenine pathways) in depression.
[16]
Transport and inhibition mechanism for VMAT2-mediated synaptic ...
Jan 2, 2024 · Monoamine neurotransmitters such as serotonin and dopamine are loaded by vesicular monoamine transporter 2 (VMAT2) into synaptic vesicles ...Missing: HIAA feedback tetrahydrobiopterin
[17]
Mouse models for inherited monoamine neurotransmitter disorders
Jan 2, 2024 · Monoamine oxidase (MAO) A and B catalyze the oxidative deamination of dopamine to HVA and serotonin to 5-HIAA. MAOA deficiency was first ...
[18]
Biochemistry, 5 Hydroxyindoleacetic Acid - StatPearls - NCBI - NIH
May 1, 2023 · 5-hydroxy indoleacetic acid (5-HIAA) is the primary metabolite of serotonin. Serotonin is broken down into 5-hydroxy indoleacetic acid within the liver.
[19]
Neuroanatomy, Nucleus Raphe - StatPearls - NCBI Bookshelf
The raphe nuclei are positioned midline in the brainstem throughout the midbrain, pons, and medulla. These nuclei contain primarily serotonergic neurons, ...
[20]
Median raphe serotonergic neurons projecting to the ...
Dec 22, 2022 · Although the dorsal raphe nucleus (DRN) and median raphe nucleus (MRN) are the main origins of serotonergic projections to the forebrain, most ...
[21]
Serotonin Neuron Diversity in the Dorsal Raphe - ACS Publications
Jan 16, 2013 · The dorsal raphe nucleus contains one of the largest groups of serotonergic neurons in the mammalian brain and is the main site of origin of the serotonergic ...
[22]
Serotonergic Mechanisms Regulating the GI Tract - PubMed Central
Serotonin (5-hydroxytryptamine; 5-HT) is best known as a neurotransmitter critical for central nervous system (CNS) development and function.Missing: definition | Show results with:definition
[23]
Sodium channel NaV1.3 is important for enterochromaffin cell ...
Nov 15, 2017 · More than 90% of the serotonin (5-hydroxytryptamine, 5-HT) in the body is produced and released into circulation by a single enteroendocrine ...
[24]
Platelet-Derived Serotonin Mediates Liver Regeneration - Science
Apr 7, 2006 · Platelets store and release serotonin. About 95% of all serotonin found in blood is stored in platelets. In vitro, serotonin is a potent ...
[25]
Serotonergic neuron markers - Abcam
Tryptophan hydroxylase (TPH2). Tryptophan hydroxylase 2 (TPH2) is an enzyme found in serotonergic neurons, primarily within the brain's raphe nuclei. It ...
[26]
Firing Properties of Genetically Identified Dorsal Raphe ...
Aug 3, 2016 · Tonic spiking of serotonergic neurons establishes serotonin levels in the brain. Since the first observations, slow regular spiking has been ...
[27]
Serotonergic neurons signal reward and punishment on multiple ...
... serotonergic neurons can use tonic as well as phasic firing to convey reward information. This raises questions as to whether these different modes of firing ...
[28]
SLC6A4 solute carrier family 6 member 4 [ (human)] - NCBI
Aug 19, 2025 · This gene encodes an integral membrane protein that transports the neurotransmitter serotonin from synaptic spaces into presynaptic neurons.
[29]
p31645 · sc6a4_human - UniProt
Serotonin transporter that cotransports serotonin with one Na + ion in exchange for one K + ion and possibly one proton in an overall electroneutral transport ...
[30]
Serotonin Receptors in Areas of the Emotion Regulation Network in ...
Jul 16, 2025 · ABSTRACT. Serotonergic neurotransmission is crucial for emotion processing and is dysregulated in mood disorders.Missing: scope | Show results with:scope
[31]
Structure and Function of Serotonin G protein Coupled Receptors
Currently, two GPCR crystal structures exist for the serotonin family, the 5-HT1B and 5-HT2B receptor, with the antimigraine and valvulopathic drug ergotamine ...2. Historic Aspects And... · 2.2 5-Ht Receptors And... · 3.2 Binding Pocket
[32]
Serotonin modulation of cortical neurons and networks - Frontiers
Apr 18, 2013 · So far, 14 different 5-HT receptor subtypes have been identified, corresponding to 7 different families: 5-HT1 (5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, ...
[33]
molecular underpinning of receptor activation and modulation - Nature
Jun 18, 2021 · The five 5-HT1 receptor structures determined by Xu and colleagues display the canonical seven-TM fold of G-protein-coupled receptors (GPCRs) ...Missing: HT7 | Show results with:HT7
[34]
Serotonergic signaling: multiple effectors and pleiotropic effects
May 9, 2012 · The 5-HT1 receptors (5-HT1R) couple primarily through Gi/o-proteins not only to inhibit AC but also to a multitude of other signaling pathways ...
[35]
Rethinking 5-HT1A Receptors: Emerging Modes of Inhibitory ...
These 5-HT1A autoreceptors exert inhibitory feedback in response to local release of serotonin in the raphe nuclei from axonal collaterals (Figure 1B).
[36]
Serotonergic Feedback Control - ScienceDirect.com
Evidence for feedback inhibition by presynaptic 5-HT1A and 5-HT1B autoreceptors is well established. ... serotonin uptake inhibitor and serotonin 5-HT1A receptor ...
[37]
5-HT 1B receptor - IUPHAR/BPS Guide to PHARMACOLOGY
View species-specific agonist tables. Agonist Comments. Frovatriptan is selective for 1B and 1D 5-HT receptor subtypes compared to the 1A subtype [92].
[38]
5-HT2A receptors: Pharmacology and functional selectivity
The 5-HT2 receptor family includes 5-HT2A, 5-HT2B, and 5-HT2C subtypes, all of which are class A rhodopsin-like GPCRs and primarily signal through Gq-mediated ...
[39]
Beyond the 5-HT2A Receptor: Classic and Nonclassic Targets in ...
Nov 8, 2023 · In this mini-review, we will discuss how the 5-HT 2A receptor activation is just one facet of the complex mechanisms of action of serotonergic psychedelics.5-Ht Receptor: An Integral... · The 5-Ht Receptor As A... · Bdnf And Trkb: Key To...Missing: postsynaptic | Show results with:postsynaptic
[40]
Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A ... - NIH
How psychedelics mediate their actions—both therapeutic and hallucinogenic—are not understood, although activation of the 5-HT2A serotonin receptor (HTR2A) is ...Missing: postsynaptic | Show results with:postsynaptic
[41]
The 5-HT3 receptor as a therapeutic target - PMC - PubMed Central
In this review, the authors look at the structure, function and distribution of 5-HT 3 receptors and how this may influence their role in disease.
[42]
Antiemetics, Selective 5-HT3 Antagonists - StatPearls - NCBI - NIH
Serotonin binding to 5-HT3 receptors triggers nausea and vomiting.[3] Serotonin 5-hydroxytryptamine-3 (5-HT3) receptor antagonists exert their activity on ...Missing: ionotropic | Show results with:ionotropic
[43]
Therapeutics of 5-HT3 Receptor Antagonists: Current Uses and ...
5-HT 3 receptor antagonists are indicated for treatment of chemotherapy, radiation, and anesthesia-induced nausea and vomiting, as well as irritable bowel ...Missing: ionotropic | Show results with:ionotropic
[44]
Structural studies of serotonin receptor family - BMB Reports
The 5-HT4, 5-HT6 and 5-HT7 receptors couple with the Gs protein to enhance AC activity and elevate cAMP levels. Notably, 5-HT4R can bind to both Gs and Gi ...
[45]
Distribution of 5-HT3, 5-HT4, and 5-HT7 Receptors Along the ...
The serotonin (5-HT) 4 receptor is expressed in several different cell types in the human colon– where it stimulates intestinal activity (ie, prokinetic action) ...
[46]
The Serotonergic System and Its Role in Thermoregulation - MDPI
Serotonin receptors have been classified as 5-HT1A-F, 5-HT2A-C, 5-HT3, 5-HT4, 5-HT5, 5-HT6 and 5-HT7. Most serotonin receptors are GPCRs and show heterogeneity, ...
[47]
The 5-Hydroxytryptamine signaling map: an overview of serotonin ...
This is hardly surprising, given that to date seven 5-HT receptor families (5-HT1–7) have been identified. These include 5-HT1A, B, D, E, F; 5-HT2A, B, C; 5- ...
[48]
Serotonin receptor signaling and regulation via β-arrestins - PMC
The involvement of GRKs and β-arrestins in the desensitization and internalization of serotonin receptors has also been demonstrated for the 5-HT4R. The 5-HT4Rs ...
[49]
5-HT1A Receptor-Mediated Autoinhibition and the Control of ...
Activity-dependent release of serotonin within serotonergic nuclei is thought to activate these autoreceptors, thus completing an autoinhibitory feedback loop.
[50]
5-HT1A receptors in mood and anxiety: recent insights into ...
In summary, this model predicts that having relatively higher levels of 5-HT1A autoreceptors results in increased susceptibility to depression and decreased ...
[51]
The neurobiology of depression—revisiting the serotonin hypothesis ...
The serotonin (5-HT) hypothesis of depression dates from the 1960s. It originally postulated that a deficit in brain serotonin, corrected by antidepressant ...
[52]
Contribution of 5-HT2 Receptor Subtypes to Sleep–Wakefulness ...
Serotonin (5-hydroxytryptamine; 5-HT) plays key roles in sleep–wakefulness regulation. Evidence indicates that 5-HT2 receptors are involved mainly in non-rapid ...5-Ht--/-- Mutants Express... · 5-Ht Mrna Expression In Cns · 5-Ht And 5-Ht Receptors Are...<|control11|><|separator|>
[53]
Serotonin control of sleep-wake behavior - ScienceDirect.com
It is currently accepted that serotonin (5-HT) functions predominantly to promote wakefulness (W) and to inhibit REM (rapid eye movement) sleep (REMS).Missing: HT2 | Show results with:HT2
[54]
Translating the promise of 5HT4 receptor agonists for the treatment ...
Animal experimental studies suggest that 5-HT 4 receptor activation holds promise as a novel target for the treatment of depression and cognitive impairment.
[55]
The role of serotonin 5-HT2A receptors in memory and cognition
Oct 6, 2015 · Serotonin 5-HT 2A receptors (5-HT 2A Rs) are widely distributed in the central nervous system, especially in brain region essential for learning and cognition.
[56]
Serotonin, food intake, and obesity - PMC - PubMed Central - NIH
In the hedonic circuitry, serotonergic signaling may reduce reward‐related, motivational food consumption. In contrast, peripherally acting serotonin promotes ...Summary · 3. Functional Organization... · 3.1. Serotonin Signaling In...
[57]
Selective serotonin receptor stimulation of the medial nucleus ...
It could be argued that 5-HT2C activation of the nucleus accumbens might increase appetitive motivation due to actions on promoting dopamine output, but that ...
[58]
Activation of Serotonin 2A Receptors Underlies the Psilocybin ...
Jun 19, 2013 · Recent evidence suggests that activation of 5-HT2A receptors may lead to the formation of visual hallucinations by increasing cortical excitability and ...
[59]
Serotonin Signaling in the Gastrointestinal Tract - PMC - NIH
Serotonin (5-HT) has been recognized for decades as an important signaling molecule in the gut, but it is still revealing its secrets.
[60]
Functions of 5-HT2A receptor and its antagonists in the ... - PubMed
5-HT(2A) receptor is associated with the contraction of vascular smooth muscle, platelet aggregation and thrombus formation and coronary artery spasms.Missing: clotting | Show results with:clotting<|separator|>
[61]
5-HT1B-receptors and vascular reactivity in human isolated blood ...
5-HT1B-receptor mediated vasoconstriction of cranial arteries is a potential mechanism by which 5-HT1B/1D-receptor agonists such as sumatriptan produce ...
[62]
5-HT and the Immune System - PMC - PubMed Central
Importantly, 5-HT attracts mast cells to sites of inflammation; injection of 5-HT into the skin produced accumulation of mast cells in wild-type but not in 5- ...
[63]
Role of 5-HT7 receptors in the immune system in health and disease
Dec 31, 2019 · 5-HT7 receptor activation induces DCs to release interleukin (IL)-1β and IL-8, while reducing the secretion of IL-12 and tumor necrosis factor ( ...
[64]
Melatonin: Pharmacology, Functions and Therapeutic Benefits - PMC
Two enzymes, found mainly in the pineal gland, transform serotonin to melatonin [17, 18]: serotonin is first acetylated to form N-acetylserotonin by ...
[65]
Serotonin regulates glucose-stimulated insulin secretion from ... - NIH
Here we show that the increased islet serotonin induced by pregnancy signals through the 5-HT3 receptor (Htr3) to increase insulin secretion dramatically.
[66]
Skeletal effects of serotonin (5-hydroxytryptamine) transporter ...
The serotonin 5-HT2B receptor controls bone mass via osteoblast recruitment and proliferation. FASEB J. 2008;22:418–27. doi: 10.1096/fj.07-9209com. [DOI] ...
[67]
Serotonin and Mental Disorders: A Concise Review on Molecular ...
In this concise review, we focus on evidence of the links between serotonin and major depressive disorders, as well as other mood disorders, anxiety disorders, ...
[68]
Serotonergic underpinnings of obsessive‐compulsive disorder: A ...
Nov 7, 2024 · Evidence is still conflicting regarding specific serotonergic-related dysfunctions in OCD. We systematically reviewed the literature to provide ...
[69]
5-HT2A receptor dysregulation in a schizophrenia relevant mouse ...
Apr 22, 2022 · Blockade of N-methyl-D-aspartate receptors (NMDAR) is known to augment cortical serotonin 2A receptors (5-HT2ARs), which is implicated in psychosis.
[70]
Mechanisms of action of the 5-HT1B/1D receptor agonists - PubMed
These actions include the release of vasoactive neuropeptides by the trigeminovascular system, vasodilation of intracranial extracerebral vessels, and increased ...Missing: vascular | Show results with:vascular
[71]
Association Between 5-HTTLPR Polymorphism and the Risk of Autism
Feb 13, 2019 · Background: Recently, many case-control studies have reported the association between 5-HTTLPR polymorphism and autism risk.
[72]
Role of serotonin in gastrointestinal motility and irritable bowel ...
Serotonin directly and indirectly affects intestinal motor and secretory function and abnormalities may lead to either constipation or diarrhea in IBS.
[73]
Carcinoid Syndrome - StatPearls - NCBI Bookshelf - NIH
These tumors secrete biogenic amines, particularly serotonin, leading to hallmark symptoms such as flushing, diarrhea, bronchospasm, and systemic complications ...
[74]
Serotonin transporter overexpression is responsible for pulmonary ...
Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest. 2001 Oct ...
[75]
The Serotonin Transporter Promoter Variant (5-HTTLPR), Stress ...
We found strong evidence that 5-HTTLPR moderates the relationship between stress and depression, with the s allele associated with an increased risk of ...
[76]
Selective Serotonin Reuptake Inhibitors - StatPearls - NCBI Bookshelf
May 1, 2023 · As the name suggests, SSRIs exert action by inhibiting the reuptake of serotonin, thereby increasing serotonin activity.
[77]
Venlafaxine - StatPearls - NCBI Bookshelf
In addition, venlafaxine is commonly used off-label for conditions such as attention-deficit disorder, fibromyalgia, diabetic neuropathy, complex pain syndromes ...Venlafaxine · Administration · Adverse Effects
[78]
Major depressive disorder: hypothesis, mechanism, prevention and ...
Feb 9, 2024 · The main representative SSRIs drugs include fluoxetine, sertraline, paroxetine, and escitalopram. The mechanisms of action of SSRIs are ...
[79]
Serotonin and norepinephrine reuptake inhibitors (SNRIs)
Mar 6, 2025 · Antidepressant SNRIs help relieve depression symptoms, such as irritability and sadness, but some are also used for anxiety disorders and nerve pain.Serotonin And Norepinephrine... · Side Effects And Cautions · Safety Issues With Snris
[80]
Sumatriptan - StatPearls - NCBI Bookshelf - NIH
Nov 12, 2023 · Based on clinical studies, sumatriptan is an effective and well-tolerated treatment for migraines when administered intravenously, ...
[81]
Triptans (serotonin, 5-HT1B/1D agonists) in migraine - PubMed
The triptans, selective serotonin 5-HT1B/1D agonists, are very effective acute migraine drugs. Soon, seven different triptans will be clinically available at 13 ...
[82]
Buspirone - StatPearls - NCBI Bookshelf - NIH
Buspirone is primarily used to treat generalized anxiety disorder. It is a United States Food and Drug Administration-approved medicine for managing anxiety ...
[83]
Pharmacotherapy for Anxiety Disorders: From First-Line Options to ...
Jun 17, 2021 · Buspirone. Buspirone, an azapirone class 5-HT1A receptor partial agonist, is FDA approved for use in generalized anxiety disorder and may ...<|separator|>
[84]
Atypical Antipsychotic Agents - StatPearls - NCBI Bookshelf - NIH
May 1, 2024 · 10. Weiden PJ. Iloperidone for the treatment of schizophrenia: an updated clinical review. Clin Schizophr Relat Psychoses. 2012 Apr;6 ...
[85]
The role of serotonin receptors in the action of atypical antipsychotic ...
5-HT2C receptor antagonism appears to contribute to the weight gain produced by some atypical APDs and may also affect cognition and psychosis via its influence ...
[86]
Psilocybin with psychological support for treatment-resistant ...
May 17, 2016 · This study provides preliminary support for the safety and efficacy of psilocybin for treatment-resistant depression and motivates further ...<|separator|>
[87]
Current Understanding on Psilocybin for Major Depressive Disorder
Nov 30, 2023 · We identified 11 clinical trials that had investigated the effect of psilocybin in the treatment of depression. Among them six were open label ...
[88]
MDMA-assisted therapy for severe PTSD: a randomized, double ...
May 10, 2021 · Together these data suggest that MDMA may exert its therapeutic effects through a well-conserved mechanism of amygdalar serotonergic function ...
[89]
MDMA and MDMA-Assisted Therapy | American Journal of Psychiatry
Dec 20, 2024 · MDMA also is predominantly serotonergic, but in contrast to classical psychedelics, MDMA blocks serotonin, norepinephrine, and dopamine reuptake ...
[90]
Deficiency of brain 5-HT synthesis but serotonergic neuron ...
The preliminary results indicate that in Tph2 knockout mice raphe neurons are completely devoid of 5-HT, whereas no obvious alteration in morphology and fiber ...
[91]
Growth retardation and altered autonomic control in mice ... - PubMed
By genetically ablating TPH2, we created mice (Tph2(-/-)) that lack serotonin ... Mice, Knockout; Respiration; Serotonin / biosynthesis; Serotonin / deficiency ...
[92]
Exaggerated aggression and decreased anxiety in mice deficient in ...
May 29, 2012 · In this study, we used Tph2-deficient (Tph2(-/-)) mice to evaluate the impact of serotonin depletion in the brain on mouse behavior. Tph2(-/-) ...
[93]
Neurochemical, behavioral, and physiological effects of ... - PubMed
Serotonin transporter (SERT) knockout (-/-) mice have an altered phenotype in adulthood, including high baseline anxiety and depressive-like behaviors ...
[94]
Hypolocomotion, anxiety and serotonin syndrome-like behavior ...
Hypolocomotion, anxiety and serotonin syndrome-like behavior contribute to the complex phenotype of serotonin transporter knockout mice. Genes Brain Behav ...
[95]
PET imaging of serotonin transporters with [11C]DASB: test-retest ...
Our results suggest that [11C]DASB parametric imaging of BP and R1 with the noninvasive MRTM2 method is reproducible and reliable for PET studies of SERT.
[96]
Estimation of serotonin transporter parameters with 11C-DASB in ...
The results of this study indicate that (11)C-DASB can be used to measure SERT parameters with high reliability and low variability in receptor-rich regions ...
[97]
Dorsal raphe serotonin neurons inhibit operant responding for ...
Nov 12, 2018 · Optogenetic stimulation of 5-HT input to the VTA combined with citalopram treatment produced a synergistic decrease in responding for saccharin, ...
[98]
Raphe serotonin projections dynamically regulate feeding behavior ...
Nov 10, 2022 · We also used optogenetics to test the effects of raphe-ZIR and raphe-PVT 5-HT projections on feeding motivation and food intake in mice ...
[99]
Optogenetic activation of 5-HT neurons in the dorsal raphe ...
Nov 13, 2017 · Optogenetic activation of 5-HT neurons in the dorsal raphe suppresses seizure-induced respiratory arrest and produces anticonvulsant effect in ...
[100]
Physiological and pharmacological properties of 5-HT3 receptors
Whole cell and patch clamp techniques were used to investigate the properties of 5-HT3 receptors of a murine neuroblastoma cell line (N1E-115) and adult rabbit ...
[101]
Single channel properties of the 5-HT3 subtype of serotonin receptor ...
Jun 20, 1994 · Whole cell and outside-out patch clamp recordings were obtained from primary cultures of rat and mouse hippocampal neurons. Serotonin (5-HT) ...
[102]
Calcium influx through presynaptic 5-HT3 receptors facilitates GABA ...
Serotonin 5-hydroxytryptamine type 3 receptors (5HT3R) are Ca2+-permeant, non-selective cation channels that have been localized to presynaptic terminals ...
[103]
Functional characterization of 5-HT 1A and 5-HT 1B serotonin ...
We propose that this approach to assay 5-HT1-mediated signaling through endogenous Gαi/o-proteins in HEK293 cells or through specific Gαi/o-subunits in a fairly ...
[104]
Characterization of serotonin-5-HTR1E signaling pathways and its ...
These findings indicate that serotonin interaction with 5-HTR1E receptor simultaneously activates cAMP and ERK pathway in HEK293 cells and its expression is ...
[105]
Allosteric Inhibition of Serotonin 5-HT 7 Receptors by Zinc Ions
Additionally, in the functional LANCE test using the constitutively active HEK293 cell line expressing the 5-HT7 receptor, 10 μM zinc had features of ...
[106]
Automated analysis of antidepressants' effect in the forced swim test
The forced swim test (FST) is a commonly used procedure of preclinical screening of drugs for the antidepressant activity. It has high predictive validity ...
[107]
Effect of Various Classes of Antidepressants in Behavioral ... - PubMed
Aug 15, 2007 · The forced swim test (FST) and tail suspension test (TST) are widely used as animal models for screening potential antidepressants.
[108]
Effect of serotonergic lesion on "anxious" behaviour measured in the ...
Lesioned rats had an increased ratio of open/total arm entries in the elevated plus-maze, reflecting a decreased level of anxiety.
[109]
An evaluation of the elevated plus-maze test using the ... - PubMed
These results suggest that an agonist action at postsynaptic 5-HT1A receptors mediates the anxiogenic-like effects of buspirone in the elevated plus-maze test ...
[110]
Effects of plus-maze experience and chlordiazepoxide on anxiety ...
The extent to which rats express anxiety-like behavior on the elevated plus-maze (EPM) depends on their previous maze experience.
[111]
CSF serotonin, 5-hydroxyindolacetic acid and neuropeptide Y levels ...
In the present study, we examined CSF 5-HT, 5-HIAA and NPY levels and correlate them with gender and suicidal behavior of severe major depressive disorder.
[112]
5-Hydroxyindoleacetic acid in cerebrospinal fluid and prediction of ...
Low concentrations of the serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA) in cerebrospinal fluid (CSF) are associated with suicidal behaviour in ...
[113]
The effects of acute tryptophan depletion on instrumental reward ...
The precise pattern of results is suggestive of a 'normalization' of reward-related neural responses during ATD in recAN compared to HC.
[114]
Acute tryptophan depletion promotes an anterior-to-posterior fMRI ...
We investigated the modulatory effect of serotonin using acute tryptophan depletion (ATD) during a cognitive switching task involving visual-spatial set ...
[115]
Functional consequences of acute tryptophan depletion on raphe ...
Feb 15, 2020 · The putative decrease in brain 5-HT synthesis via ATD significantly alters FC of the raphe nuclei as well as of specific subcortical/cortical regions.
[116]
Psilocybin - Usona Institute
“ In 2019, the FDA granted Breakthrough Therapy designation to Usona's Investigational New Drug application for psilocybin as a potential treatment for major ...Missing: 2020s | Show results with:2020s
[117]
A Study of Psilocybin for Major Depressive Disorder (MDD ...
The purpose of this study is to evaluate the potential efficacy of a single 25 mg oral dose of psilocybin for MDD compared to the active placebo.
[118]
FDA Grants Breakthrough Therapy Designation to CYB003, a ...
Jun 3, 2024 · The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to CYB003, a novel psychedelic compound developed by Cybin Inc.Missing: 2020s | Show results with:2020s
[119]
Enhancement of 5-HT2A receptor function and blockade of Kv1.5 by ...
Apr 27, 2018 · They found that both ketamine and MK801 blocked the switch and enhanced activity of serotonin receptors, with MK801 having a stronger effect ...
[120]
Vilazodone, a Novel SSRI Antidepressant with 5-HT1A Partial ...
Oct 28, 2024 · In contrast to prototypical SSRIs such as fluoxetine, vilazodone also acts as a partial 5-HT1A serotonin receptor agonist and is thus proposed ...Missing: modulator | Show results with:modulator
[121]
The antidepressant drug vilazodone is an allosteric inhibitor ... - Nature
Aug 20, 2021 · Vilazodone (viibryd®; VLZ, Supplementary Fig. 1) is a clinically approved SSRI which also has activity as a 5-HT1A receptor partial agonist. Its ...
[122]
Current Limitations and Candidate Potential of 5-HT7 Receptor ...
Feb 18, 2021 · Therefore, 5-HT7R antagonism is possibly more effective in cognitive impairment and mood disturbances than against core (positive and negative) ...
[123]
Targeting the Serotonin 5-HT7 Receptor in the Search for ... - PMC
Pro-cognitive effects of 5-HT7R antagonists in animal models of schizophrenia have been supported by several studies. Specifically, deficits of prefrontal ...
[124]
Study Details | Imaging 5HT7 Antagonist Effects in Bipolar Disorder
The main aim of this research is to examine the potential of 5HT7 antagonists for the treatment of cognitive impairment in bipolar disorder by determining ...<|separator|>
[125]
Multi-omics analysis of fecal microbiota transplantation's impact on ...
Dec 7, 2023 · FMT can relieve patients' constipation, depression, and anxiety symptoms by reshaping gut microbiota. The 5-HT level was associated with an ...
[126]
Fecal Microbiota Transplantation in Irritable Bowel Syndrome - MDPI
Sep 26, 2023 · This systematic review and meta-analysis aimed to ascertain the effectiveness of FMT in relieving symptoms in IBS patients.
[127]
Clinical efficacy of fecal microbiota transplantation in alleviating ...
Oct 6, 2025 · This meta-analysis supports FMT as an effective adjunctive therapy for depressive symptoms, especially in individuals with IBS. Endoscopic or ...Missing: enteric | Show results with:enteric
[128]
Human Serotonin Transporter Gene (SLC6A4) Variants
In a recent report, SERT expression was shown to be modulated by 3′-UTR microRNAs, with miR-16 found to be a posttranscriptional regulator of SERT levels. Over- ...
[129]
Stress inhibits tryptophan hydroxylase expression in a rat model of ...
Sep 8, 2017 · The location and function of TPH2 has made it an essential candidate gene in many mental disorders, including depression. Currently, the ...Missing: overexpression | Show results with:overexpression
[130]
Two models of inescapable stress increase tph2 mRNA expression ...
Expression of TPH2, the rate-limiting enzyme for brain serotonin synthesis, is elevated in the dorsal raphe nucleus (DR) of depressed suicide victims.
[131]
5-HT2 Agonist Clinical Trial Pipeline Appears Robust With 20+ Key ...
Jan 22, 2025 · In October 2024, Bright Minds Biosciences Inc. a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of ...
[132]
Lorcaserin, A 5-HT 2C Receptor Agonist, Reduces Body Weight by ...
The purpose of this study was to test the effect of lorcaserin on EI, appetite ratings, and EE in overweight and obese individuals. Subjects and Methods. Ethics.
[133]
Remote Electrical Neuromodulation (REN) Relieves Acute Migraine ...
May 9, 2019 · A recent pilot study showed that REN can significantly reduce headache. We have conducted a randomized, double-blind, sham-controlled study to ...
[134]
Remote electrical neuromodulation (REN) in the acute treatment of ...
Jul 22, 2019 · REN is an effective acute treatment for migraine with non-inferior efficacy compared to current acute migraine therapies.